ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celularity pursues placental stem cells

by Ryan Cross
February 26, 2018 | APPEARED IN VOLUME 96, ISSUE 9

Celularity has officially launched with $250 million in funding to develop treatments for cancer, autoimmune disease, diabetes, and even aging, all from placenta-derived stem cells. These stem cells, unlike blood stem cells, do not need to be matched to a patient’s immune system, making them an attractive option for use in many areas of medicine, including CAR-T immunotherapy and regenerative medicine.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment